Skip to main content
Equibles
AURX logo

AURX · Nuo Therapeutics, Inc.

Track AURX — free

Use AURX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.14 +0.04 (+3.64%) At close · Aug 31
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products and the Private Label product to Smith+Nephew are insufficient to support our operations for the next 12 months from the date these financial statements are issued. As such, we believe that substantial doubt about our ability to continue as a going concern exists.”
View the 10-Q filed Aug 14, 2026
Market Cap
$53.28M
Shares
48.43M

AURX metrics

62 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.14
Market cap
$53.28M

Price action

19 metrics
Price change (1W)
+6.5%
Price change (30D)
+34.1%
Price change (3M)
+11.8%
Price change (6M)
-18.6%
Price change (YTD)
-42.1%
Price change (1Y)
-30.1%
Trailing year
Price change (5Y)
+393.5%
52-week high
$3.23
52-week low
$0.77
Change from 52-week high
-64.7%
Change from 52-week low
+48.1%
Annualized volatility
118.3%
Beta
-0.4
RSI (14D)
59.1
Price vs SMA 50
+10.5%
Price vs SMA 200
-30.1%
Avg volume (3M)
4,488
Relative volume
1.4
Average dollar volume
$4,604

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
48.43M

Valuation

12 metrics
P / E (TTM)
4.2
Trailing earnings · reciprocal yield 23.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
10.2×
reciprocal yield 9.8%
P / book
—
FCF yield
-4.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
64.1%
Operating margin
-33.3%
Trailing 12 months
Net margin
-38.7%
Gross profit (TTM)
$3.33M
Operating profit (TTM)
−$1.73M
Net income (TTM)
−$2.01M
Trailing 12 months
Diluted EPS (TTM)
$0.27
FCF margin
-47.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.02

Growth

11 metrics
Revenue growth YoY
+152.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$5.20M
Trailing 12 months
EPS growth YoY
-111.1%
Shares change YoY
+24.8%
Year over year · more shares
Revenue CAGR (3Y)
+209.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-76.6%
Debt / equity
—
Current ratio
1.3
EBITDA (TTM)
−$879,339
Free cash flow (TTM)
−$2.45M
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$449,325
Total assets
$2.63M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.15M
Capital expenditures (TTM)
$297,079
R&D (TTM)
$0
SG&A (TTM)
$5.07M
Stock compensation (TTM)
$108,459
R&D / revenue
—
Stock compensation / revenue
2.1%

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
30 / 100

Insider activity

2 metrics
Net insider buying (90D)
$9,539
Insider-sentiment score
76 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1091596 CUSIP 67059V209 Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)